Content Type: Commentary & Opinion

The Puzzle of Biologics Manufacturing Platform Patents (Reply)

March 6, 2026

Opioid Settlements in Canada: Avoiding U.S. Pitfalls, Embracing Best Practices

March 6, 2026

Strategies to Advance Drug Repurposing for Rare Diseases

March 6, 2026

Drug Versioning and Legal Accountability for Preventable Product Harms

March 6, 2026

Op-Ed: The Trouble with ‘Do Your Own Research’ for Drugs

March 6, 2026

What Can We Learn From Patient Input at FDA Advisory Committee Meetings?

March 6, 2026

Congress Should Remove the Rare Disease Carve-Out From Medicare Drug Price Negotiation, Not Expand It

March 6, 2026

Real-World Evidence Is a Vital Tool for Informing Treatment Strategies in Chronic Obstructive Pulmonary Disease

March 6, 2026

Active Postmarketing Device Surveillance as a Legislative Priority

March 6, 2026

Patent Thickets and Product Hops: Challenges and Opportunities for Legislative Reform

March 6, 2026

Engaging Pharmacists in Strategies for Navigating Prescription Drug Costs (Reply)

March 6, 2026

Op-Ed: It’s Not Hard to See Through RFK Jr.’s ‘Radical Transparency’ Pledge

March 6, 2026